Quantum BioPharma Provides Corporate Update

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates. Quantum Biopharma has retained the services of FinnCom, Inc. (“ FinnCom ”), on a six-month contract with option for renewal, starting June 24, 2026, to provide marketing and investor awareness services. FinnCom is an arm's-length marketing, advertising and shareholder relations firm based in Lancaster, California. FinnCom will design and execute campaigns that include corporate branding, social media, and advertising initiatives. Under the terms of the agreement, the Company will pay FinnCom USD 20,500 at contract initiation, followed by six monthly payments of USD 25,000 from July 2026 to December 2026, included. The total cash consideration to FinnCom is USD 170,500. To the Company's knowledge, FinnCom does not own any shares, options, or warrants in Quantum Biopharma. About Quantum BioPharma Ltd. Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), Quantum BioPha...